Assembly Biosciences Reports Positive Phase 1b Results for Hepatitis B Drug ABI-4334

Reuters

Nov 07, 2025

Assembly Biosciences Reports Positive Phase 1b Results for Hepatitis B Drug ABI-4334

Assembly Biosciences Inc. announced positive results from a Phase 1b clinical study of its investigational capsid assembly modulator, ABI-4334, in patients with HBeAg-negative chronic hepatitis B infection not suppressed on nucleoside analogues. The data, which demonstrated a favorable safety and tolerability profile as well as potent reductions in viral nucleic acids, were presented in a late-breaking poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, held November 7-11, 2025, in Washington, D.C. The study evaluated oral doses of 150 mg and 400 mg of ABI-4334 given once daily over 28 days, with both doses showing multi-log declines in hepatitis B virus DNA and pregenomic RNA. ABI-4334 has not been approved for use, and its safety and efficacy have not yet been established.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570912-en) on November 07, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581881668"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581881668\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581881668?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581881668","market":"fut","top_or_hot":-1,"title":"Assembly Biosciences Reports Positive Phase 1b Results for Hepatitis B Drug ABI-4334","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Assembly Biosciences Reports Positive Phase 1b Results for Hepatitis B Drug ABI-4334\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASMB\">Assembly Biosciences Inc.</a> announced positive results from a Phase 1b clinical study of its investigational capsid assembly modulator, ABI-4334, in patients with HBeAg-negative chronic hepatitis B infection not suppressed on nucleoside analogues. The data, which demonstrated a favorable safety and tolerability profile as well as potent reductions in viral nucleic acids, were presented in a late-breaking poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, held November 7-11, 2025, in Washington, D.C. The study evaluated oral doses of 150 mg and 400 mg of ABI-4334 given once daily over 28 days, with both doses showing multi-log declines in hepatitis B virus DNA and pregenomic RNA. ABI-4334 has not been approved for use, and its safety and efficacy have not yet been established.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570912-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assembly Biosciences Reports Positive Phase 1b Results for Hepatitis B Drug ABI-4334</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssembly Biosciences Reports Positive Phase 1b Results for Hepatitis B Drug ABI-4334\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Assembly Biosciences Reports Positive Phase 1b Results for Hepatitis B Drug ABI-4334\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ASMB\">Assembly Biosciences Inc.</a> announced positive results from a Phase 1b clinical study of its investigational capsid assembly modulator, ABI-4334, in patients with HBeAg-negative chronic hepatitis B infection not suppressed on nucleoside analogues. The data, which demonstrated a favorable safety and tolerability profile as well as potent reductions in viral nucleic acids, were presented in a late-breaking poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, held November 7-11, 2025, in Washington, D.C. The study evaluated oral doses of 150 mg and 400 mg of ABI-4334 given once daily over 28 days, with both doses showing multi-log declines in hepatitis B virus DNA and pregenomic RNA. ABI-4334 has not been approved for use, and its safety and efficacy have not yet been established.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570912-en) on November 07, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和数据","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL5Wklws:1","article_id":"2581881668","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581881668","pubTimestamp":1762520425,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Assembly Biosciences Inc. announced positive results from a Phase 1b clinical study of its investigational capsid assembly modulator, ABI-4334, in patients with HBeAg-negative chronic hepatitis B infection not suppressed on nucleoside analogues. The data, which demonstrated a favorable safety and tolerability profile as well as potent reductions in viral nucleic acids, were presented in a late-breaking poster at the American Association for the Study of Liver Diseases  The Liver Meeting, held November 7-11, 2025, in Washington, D.C. The study evaluated oral doses of 150 mg and 400 mg of ABI-4334 given once daily over 28 days, with both doses showing multi-log declines in hepatitis B virus DNA and pregenomic RNA. ABI-4334 has not been approved for use, and its safety and efficacy have not yet been established.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-gen","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","ASMB":"Assembly Biosciences Inc.","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Assembly Biosciences报告乙型肝炎药物ABI-4334的1b期阳性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ASMB":0.9},"content_text":"Assembly Biosciences Reports Positive Phase 1b Results for Hepatitis B Drug ABI-4334\n    \n\nAssembly Biosciences Inc. announced positive results from a Phase 1b clinical study of its investigational capsid assembly modulator, ABI-4334, in patients with HBeAg-negative chronic hepatitis B infection not suppressed on nucleoside analogues. The data, which demonstrated a favorable safety and tolerability profile as well as potent reductions in viral nucleic acids, were presented in a late-breaking poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, held November 7-11, 2025, in Washington, D.C. The study evaluated oral doses of 150 mg and 400 mg of ABI-4334 given once daily over 28 days, with both doses showing multi-log declines in hepatitis B virus DNA and pregenomic RNA. ABI-4334 has not been approved for use, and its safety and efficacy have not yet been established.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9570912-en) on November 07, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}